Alunbrigtm Tablets
PDF Leaflet Revision Date: 17 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Monotherapy for ALK-positive advanced NSCLC in adults.
Dosage (summary)
Starting dose: 90 mg once daily for 7 days, then 180 mg once daily.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; breastfeeding should be discontinued during treatment.
Key Drug Interactions
- Strong CYP3A inhibitors
- Strong CYP3A inducers
- Grapefruit juice
Contraindications
- Hypersensitivity
- Pregnancy
Common side effects
- Increased AST
- Increased CPK
- Hyperglycaemia
- Diarrhoea
- Fatigue
Counselling Points
- Monitor for respiratory symptoms
- Avoid grapefruit
- Use contraception during treatment
Serious warnings
- Pulmonary adverse reactions
- Hypertension
- Bradycardia
- Visual disturbances
Important Disclaimer
The Alunbrigtm Tablets professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
